The newest generation of antiobesity medications (AOMs)—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), dual action GLP-1/GIP combinations, triple action injectables, and emerging injectable and oral medications—have changed the landscape for weight management, bringing weight loss success to many for whom weight maintenance had previously not been possible.
Trending
- How Eating Primes Immune Cells for Future Responses
- The Role of Real-World Food Testing in Celiac Disease Management
- Polycystic Ovary Syndrome* Subtypes and Precision Medicine
- The Role of Nutrition in Endometriosis
- Emulsifiers, Dysphagia, & Gut Health
- Interdisciplinary Care Starts Here
- Promoting Agricultural Resilience
- CPE Monthly: Understanding GLP-1 Receptor Agonists